Država: Australija
Jezik: engleski
Izvor: Department of Health (Therapeutic Goods Administration)
irinotecan hydrochloride trihydrate, Quantity: 100 mg
Pfizer Australia Pty Ltd
Injection, concentrated
Excipient Ingredients: sorbitol; sodium hydroxide; water for injections; lactic acid; dilute hydrochloric acid
Intravenous
Single Pack
(S4) Prescription Only Medicine
Irinotecan injection is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. Irinotecan injection is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
Visual Identification: A clear, colourless to pale yellow solution free from visible particulate matter.; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius
Licence status A
2005-02-15
DBL™ Irinotecan Injection Concentrate CMI page 1 DBL™ IRINOTECAN INJECTION CONCENTRATE Irinotecan _(eye-ri-noe-TEE-kan)_ Hydrochloride trihydrate CONSUMER MEDICINE INFORMATION _DATE OF DISPENSING_ _CONSUMER NAME _ _PHARMACIST NAME _ _CONSUMER ADDRESS _ _PHARMACIST ADDRESS _ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about DBL™ Irinotecan Injection Concentrate. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you being given irinotecan against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET._ _ You may need to read it again. WHAT IRINOTECAN IS USED FOR This medicine is used to treat cancer of the colon or rectum that has: • spread to other parts of the body, or • recurred or progressed following initial therapy. This medicine belongs to a group of medicines called antineoplastic or cytotoxic medicines. You may also hear of these being called chemotherapy medicines. It works by killing cancer cells and stopping cancer cells from growing and multiplying. It may be used alone or in combination with other medicines to treat cancer. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU . Your doctor may have prescribed it for another reason. This medicine is not addictive. _ _ It is available only with a doctor’s prescription. There is not enough information to recommend the use of this medicine for children. BEFORE YOU ARE GIVEN IT _WHEN YOU MUST NOT BE _ _GIVEN IT _ YOU MUST NOT BE GIVEN DBL™ IRINOTECAN INJECTION CONCENTRATE IF YOU HAVE AN ALLERGY TO: • any medicine containing irinotecan hydrochloride trihydrate • any of the ingredients listed at the end of this leaflet. Some of the symptoms of an allergic reaction may include: • shortness of breath • wheezing or difficulty breathing Pročitajte cijeli dokument
Version pfpirini10319 Supersedes:8.0 Page 1 of 34 AUSTRALIAN PRODUCT INFORMATION DBL ™ IRINOTECAN INJECTION CONCENTRATE (IRINOTECAN HYDROCHLORIDE TRIHYDRATE) 1. NAME OF THE MEDICINE Irinotecan hydrochloride trihydrate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION The 2 mL and 5 mL injections contain 40 mg and 100 mg of irinotecan hydrochloride trihydrate respectively. In addition to irinotecan hydrochloride trihydrate, the ingredients are sorbitol and lactic acid. Sodium hydroxide and hydrochloric acid are used for pH adjustment. Irinotecan hydrochloride trihydrate is a semisynthetic derivative of camptothecin, an alkaloid extract from plants such as _Camptotheca acuminata_ . It is a pale yellow to yellow crystalline powder, with the empirical formula C 33 H 38 N 4 O 6 .HCl.3H 2 O and a molecular weight of 677.19. Irinotecan hydrochloride trihydrateis slightly soluble in water and organic solvents. EXCIPIENT(S) WITH KNOWN EFFECT • Sodium hydroxide • Sorbitol For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Concentrated injection. DBL ™ Irinotecan Injection Concentrate is supplied as a sterile, pale yellow, clear, aqueous concentrated solution for injection of pH 3.5. It is intended for dilution with 5% Glucose Injection or 0.9% Sodium Chloride Injection prior to infusion. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS _ _ DBL ™ Irinotecan Injection Concentrate is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. DBL ™ Irinotecan Injection Concentrate is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy. Version pfpirini10319 Supersedes:8.0 Page 2 of 34 4.2 DOSE AND METHOD OF ADMINISTRATION It is recommended that patients receive premedication with anti-emetic agents. Prophylactic or therapeutic administration of atropine should be considered in patients experiencing cholinergic symptoms (see Section 4.4 S Pročitajte cijeli dokument